Extend your brand profile by curating daily news.

NanoViricides Advances NV-387 Into Phase 2 Trials for Ebola and Mpox

By Advos•
NanoViricides has initiated two Phase 2 clinical trials for its broad-spectrum antiviral NV-387, targeting Ebola Bundibugyo virus disease and mpox, while also pursuing measles development with FDA designations.
NanoViricides Advances NV-387 Into Phase 2 Trials for Ebola and Mpox

NanoViricides, Inc. (NYSE American: NNVC) has moved its broad-spectrum antiviral candidate NV-387 Oral Gummies into two separate Phase 2 clinical trials, according to the company’s quarterly report on Form 10-Q for the fiscal quarter ended Sept. 30, 2026. Enrollment began Sept. 23 for a trial evaluating NV-387 against Ebola Bundibugyo virus disease in the Democratic Republic of the Congo, while a separate Phase 2 trial site opened the same day to evaluate the treatment for mpox. The dual trial launches mark a significant step for a clinical-stage company seeking to address infectious diseases that lack adequate treatment options, and they signal growing momentum for a drug designed to work across multiple viral threats.

The company said it has funded the Ebola trial independently and established clinical testing infrastructure, including on-site molecular diagnostic capabilities, to support its research. That self-funding approach is notable because it reduces reliance on external partners for a program targeting a rare and often deadly virus. For investors, the progress demonstrates that NanoViricides is executing on its clinical roadmap despite the lengthy and capital-intensive nature of drug development. The company has previously cautioned that the path to typical drug development is extremely lengthy and requires substantial capital, and that there can be no assurance that its candidates will show sufficient effectiveness and safety for human clinical development.

NanoViricides also highlighted U.S. Food and Drug Administration Orphan Drug and Rare Pediatric Disease designations granted to NV-387 for measles treatment in April and May 2026, respectively. The company plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to advance development. Those designations can provide incentives such as market exclusivity and priority review, and the pursuit of nondilutive funding could help the company advance its pipeline without additional equity dilution. NV-387 remains investigational, with its effectiveness for these indications under clinical evaluation.

The broader implication is that a single antiviral candidate is being tested against several high-consequence pathogens—Ebola, mpox, and measles—at a time when global health authorities continue to monitor outbreaks and gaps in preparedness. If NV-387 proves safe and effective, it could offer a platform approach to treating multiple viral diseases rather than a single-target therapy. For the industry, the trials add to the body of clinical evidence for broad-spectrum antivirals, a category that has attracted increased attention since the COVID-19 pandemic. For readers, the news matters because it reflects ongoing efforts to develop treatments for diseases that can cause severe outbreaks, particularly in regions with limited medical infrastructure.

NanoViricides describes itself as a clinical-stage company creating special purpose nanomaterials for antiviral therapy, with NV-387 as its lead candidate for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. The company’s other advanced candidate is NV-HHV-1 for shingles. Its business model is based on licensing technology from TheraCour Pharma, Inc. for specific antiviral application verticals. As with any drug development effort, there can be no assurance at this time that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.

For a closer look at the company, visit NanoViricides, Inc. (NYSE American: NNVC), and the full press release is available at https://ibn.fm/HChFn. The company’s website is www.nanoviricides.com, and the latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN.

Advos

Advos

@advos